Encouraging clinical trial results for multiple myeloma treatment
ACY-1215 inhibits the enzyme HDAC6 in order to encourage apoptosis in multiple myeloma cells.
Evaluation of a new histone deacetylase (HDAC) inhibitor in clinical trials has led to some encouraging results, according to manufacturer Acetylon Pharmaceuticals Inc.
Developed to treat relapsed or refractory multiple myeloma, a type of bone marrow cancer, ACY-1215 has demonstrated early promise in a combinatory drug treatment course.
Eight of the ten patients involved in a phase 1b study showed disease response when taking a prescription of the medicine alongside Revlimid, which is used in mantle cell lymphoma therapy.
A phase 1/2 clinical trial in which ACY-1215 was combined with Velcade (bortezomib) also indicated that the drug could be effective in safely improving bone marrow composition.
Experimenters believe that the medicine helps boost patient condition by inhibiting the intracellular histone HDAC6 in order to disrupt protein levels and proliferative signals.
The process leads to apoptosis, programmed cell death which leaves healthy cells unharmed and thus reduces the risk of serious side-effects in patients, as is witness with chemotherapy.
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.